Here the company is building eight manufacturing trains capable of producing tens of tonnes/year of small molecules, plus peptide R&D facilities, cGMP kilo labs and a pilot plant. It will be able to support projects at all stages, Fitzharris confirmed.
The former Emergent Biosolutions facility is Syngene’s first in the US
Peptides boom continues
Undoubtedly the largest single announcement at DCAT Week came in peptides from CordenPharma , which will invest €1 billion over the next three years to establish a €500 million+ solid-phase peptide synthesis facility (SPPS) at Getec Park in Muttenz near Basel, Switzerland. Commercial activities should begin in 1H 2028. The long-term aim is to take the peptide platform business’s sales above €1 billion by 2028.
Indian CRDMO Syngene acquired animal health sectors when it becomes a biologics facility in Baltimore available for projects in 2H 2025. from Emergent BioSolutions just
The facility was in the news during the before DCAT Week 2025. The overall COVID-19 when it was repurposed from investment is estimated around $50 mAbs to vaccines under Operation million, including $36.5 million to buy it Warp Speed but suffered a mix-up in and expenses to make it operational. the manufacture of different vaccines, In India, Syngene has around 8,000 leading to its closure. Addressing employees, including 1,500 PhDs, this was a key part of Syngene’s due at sites in Bengaluru, Hyderabad diligence, Del Priore said. Now it is being and Mangalore. This is its first converted back to mAb production site outside India. and rectified. He expects the first
CEO Dr Michael Quirmbach told SCM that the 5,000 L of initial capacity in three large- and smallscale trains is already 90% booked out. The investment was driven in roughly equal measures by GLP-1s and ‘natural’ peptides, but can pivot to either as demand patterns change.
“80% of our business is in the US and GMP batch to be produced by the about 70% of our 450 clients are here,” end of the year. Alex Del Priore, SVP of the company’s Another Indian firm, Suven Pharma , Manufacturing Services division told has invested heavily in ADCs, SCM. “We were looking for a couple of linkers and high potency, with the years for the right acquisition in the US acquisition of New Jersey-based … This allows us access to the 70% of NJ Bio at Princeton in December the US pharma companies who do not 2024, as well as in small-scale export or use offshore CDMOs.” oligonucleotide manufacturing. It has
“GLP-1s were originally developed for diabetes but really took off for obesity,” Quirmbach observed. The potential remains stratospheric; his only real concern is how long insurers will continue to fund treatments that can cost $1,100/month, particularly if patients do not also change their lifestyle.
The Department of Agriculture also built a new 400,000 L raw material
This is all part of a strategic €1 billion+ investment in peptides, which will take the company’s total SPPS capacity to 17,000 L now and 47,000 L by2028. That figure includes downstream capacity at Boulder, Colorado, where a €500 million expansion was announced in 2024, and the small-scale SPPS facility in Frankfurt, Germany that was awarded GMP certification for clinical trial peptide manufacturing in 2025.
(USDA), which co-regulates animal facility in Hyderabad. health alongside the FDA, does not
“There has been a lot of talk about permit the import of mAbs from most people diversifying their supply base countries because of concerns about and moving out of China,” Dr Hugh diseases like avian flu. Thus it is a big McManus, executive head of business advantage in this market in particular to development, told SCM. “We realised have US manufacturing. that if this is the case we have to be
The facility is fitted with multiple ready to make our own raw materials if mAb lines and will bring Syngene’s we want to be fully integrated.” total single-use bioreactor capacity Suven is now waiting for the initial to 50,000 L for large molecules for trickle of RFPs to develop. However, both human and animal health. The McManus warned that China is “still company added that this will bring cell integral to the success of biotechs in line development, process optimisation the US”. There is simply not enough and both clinical and commercial replacement capacity for everything to supply to customers in the pharma and move out of China.